| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 77 | 2024 | 799 | 12.080 |
Why?
|
| Brain Injuries, Traumatic | 52 | 2024 | 353 | 10.590 |
Why?
|
| Cerebrovascular Circulation | 23 | 2017 | 512 | 3.910 |
Why?
|
| Brain Concussion | 19 | 2024 | 217 | 3.740 |
Why?
|
| Intracranial Hypertension | 18 | 2023 | 126 | 3.090 |
Why?
|
| Erythropoietin | 10 | 2019 | 219 | 2.910 |
Why?
|
| Intracranial Pressure | 17 | 2023 | 198 | 2.790 |
Why?
|
| Glasgow Outcome Scale | 11 | 2024 | 49 | 2.690 |
Why?
|
| Monitoring, Physiologic | 12 | 2023 | 535 | 1.780 |
Why?
|
| Glasgow Coma Scale | 25 | 2024 | 214 | 1.770 |
Why?
|
| Biomarkers | 24 | 2024 | 5105 | 1.410 |
Why?
|
| Erythrocyte Transfusion | 4 | 2015 | 210 | 1.390 |
Why?
|
| Recovery of Function | 10 | 2021 | 687 | 1.340 |
Why?
|
| Critical Care | 11 | 2016 | 809 | 1.330 |
Why?
|
| Brain | 20 | 2022 | 4253 | 1.270 |
Why?
|
| Oxygen | 9 | 2020 | 799 | 1.140 |
Why?
|
| Hemoglobins | 4 | 2019 | 485 | 1.080 |
Why?
|
| Neuroprotective Agents | 5 | 2012 | 219 | 1.030 |
Why?
|
| Cerebral Cortex | 10 | 2016 | 637 | 1.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 7 | 2023 | 172 | 1.010 |
Why?
|
| Post-Concussion Syndrome | 3 | 2021 | 54 | 1.000 |
Why?
|
| Hypothermia, Induced | 2 | 2016 | 177 | 0.960 |
Why?
|
| Arginine | 7 | 2018 | 509 | 0.950 |
Why?
|
| Trauma Severity Indices | 5 | 2021 | 98 | 0.940 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2022 | 532 | 0.920 |
Why?
|
| Nitric Oxide | 8 | 2018 | 664 | 0.910 |
Why?
|
| Disability Evaluation | 3 | 2021 | 243 | 0.830 |
Why?
|
| Shock, Hemorrhagic | 2 | 2012 | 79 | 0.750 |
Why?
|
| Intensive Care Units | 3 | 2015 | 742 | 0.740 |
Why?
|
| Adult | 76 | 2024 | 81480 | 0.730 |
Why?
|
| Microdialysis | 6 | 2015 | 70 | 0.720 |
Why?
|
| Longitudinal Studies | 8 | 2023 | 2049 | 0.710 |
Why?
|
| Interleukin-10 | 2 | 2020 | 481 | 0.710 |
Why?
|
| Humans | 130 | 2024 | 270852 | 0.700 |
Why?
|
| Injury Severity Score | 10 | 2020 | 243 | 0.700 |
Why?
|
| Hemodynamics | 3 | 2015 | 971 | 0.690 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 3 | 2020 | 10 | 0.680 |
Why?
|
| Cytokines | 3 | 2020 | 2836 | 0.660 |
Why?
|
| Anemia | 3 | 2014 | 733 | 0.640 |
Why?
|
| Rats, Long-Evans | 10 | 2019 | 115 | 0.640 |
Why?
|
| Craniocerebral Trauma | 3 | 2014 | 153 | 0.620 |
Why?
|
| Blood Flow Velocity | 7 | 2010 | 544 | 0.620 |
Why?
|
| Brain Injuries, Diffuse | 1 | 2017 | 1 | 0.610 |
Why?
|
| Brain Ischemia | 4 | 2004 | 316 | 0.610 |
Why?
|
| Male | 85 | 2024 | 128407 | 0.590 |
Why?
|
| Young Adult | 33 | 2024 | 22014 | 0.590 |
Why?
|
| Rats | 21 | 2023 | 6660 | 0.590 |
Why?
|
| Prospective Studies | 29 | 2024 | 13338 | 0.570 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 177 | 0.570 |
Why?
|
| Markov Chains | 1 | 2017 | 178 | 0.560 |
Why?
|
| Interleukin-2 | 1 | 2020 | 893 | 0.560 |
Why?
|
| Disease Models, Animal | 12 | 2018 | 7460 | 0.550 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 4390 | 0.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 846 | 0.530 |
Why?
|
| Middle Aged | 56 | 2024 | 89908 | 0.530 |
Why?
|
| Arginase | 2 | 2018 | 42 | 0.510 |
Why?
|
| Head Injuries, Closed | 4 | 2012 | 47 | 0.490 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2014 | 19 | 0.490 |
Why?
|
| Models, Theoretical | 1 | 2019 | 803 | 0.480 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 80 | 0.480 |
Why?
|
| Female | 69 | 2024 | 148432 | 0.480 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2015 | 71 | 0.480 |
Why?
|
| Endocrine System Diseases | 1 | 2015 | 91 | 0.470 |
Why?
|
| White Matter | 3 | 2022 | 186 | 0.470 |
Why?
|
| Homeostasis | 5 | 2008 | 961 | 0.470 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2023 | 661 | 0.460 |
Why?
|
| Prognosis | 18 | 2023 | 22421 | 0.440 |
Why?
|
| Models, Cardiovascular | 2 | 2005 | 189 | 0.440 |
Why?
|
| Animals | 44 | 2023 | 62835 | 0.440 |
Why?
|
| Nitric Oxide Synthase Type III | 3 | 2018 | 278 | 0.440 |
Why?
|
| Oligopeptides | 2 | 2012 | 452 | 0.440 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2005 | 190 | 0.430 |
Why?
|
| Behavior, Animal | 2 | 2017 | 758 | 0.420 |
Why?
|
| Neurophysiological Monitoring | 4 | 2016 | 36 | 0.410 |
Why?
|
| Antioxidants | 3 | 2023 | 520 | 0.390 |
Why?
|
| Logistic Models | 3 | 2017 | 3435 | 0.390 |
Why?
|
| Adolescent | 25 | 2022 | 32578 | 0.380 |
Why?
|
| Blood Pressure | 5 | 2005 | 1600 | 0.380 |
Why?
|
| Reaction Time | 1 | 2012 | 243 | 0.370 |
Why?
|
| Alcoholic Intoxication | 1 | 2010 | 13 | 0.370 |
Why?
|
| Disabled Persons | 2 | 2023 | 113 | 0.370 |
Why?
|
| Blood Transfusion | 4 | 2019 | 581 | 0.370 |
Why?
|
| Consciousness | 1 | 2010 | 55 | 0.360 |
Why?
|
| Head Injuries, Penetrating | 2 | 2020 | 6 | 0.360 |
Why?
|
| Cohort Studies | 13 | 2024 | 9425 | 0.350 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2010 | 171 | 0.340 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 220 | 0.330 |
Why?
|
| Oxygen Consumption | 2 | 2008 | 423 | 0.320 |
Why?
|
| Models, Statistical | 1 | 2015 | 1150 | 0.320 |
Why?
|
| Time Factors | 16 | 2021 | 13122 | 0.320 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2024 | 7780 | 0.320 |
Why?
|
| Nitric Oxide Synthase | 3 | 2004 | 329 | 0.310 |
Why?
|
| Length of Stay | 1 | 2015 | 2013 | 0.310 |
Why?
|
| Hematoma, Subdural, Acute | 2 | 2004 | 13 | 0.300 |
Why?
|
| Resilience, Psychological | 2 | 2022 | 70 | 0.300 |
Why?
|
| Neurosciences | 1 | 2008 | 51 | 0.300 |
Why?
|
| Decompressive Craniectomy | 2 | 2017 | 14 | 0.300 |
Why?
|
| Brain Chemistry | 2 | 2004 | 172 | 0.290 |
Why?
|
| Third-Party Consent | 1 | 2007 | 30 | 0.280 |
Why?
|
| Critical Illness | 3 | 2008 | 743 | 0.280 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2008 | 130 | 0.280 |
Why?
|
| Human Experimentation | 1 | 2007 | 50 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 2664 | 0.270 |
Why?
|
| Cerebral Arteries | 2 | 2003 | 100 | 0.270 |
Why?
|
| Ventriculostomy | 1 | 2006 | 42 | 0.260 |
Why?
|
| Depressive Disorder, Major | 2 | 2023 | 426 | 0.260 |
Why?
|
| Hyperoxia | 1 | 2008 | 138 | 0.260 |
Why?
|
| Trauma Centers | 7 | 2021 | 186 | 0.260 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 78 | 0.260 |
Why?
|
| Emergency Medical Services | 2 | 2007 | 461 | 0.250 |
Why?
|
| Cyclic GMP | 1 | 2005 | 123 | 0.250 |
Why?
|
| Aged | 26 | 2024 | 73012 | 0.240 |
Why?
|
| Subarachnoid Hemorrhage, Traumatic | 1 | 2024 | 1 | 0.240 |
Why?
|
| Deoxyguanosine | 1 | 2004 | 32 | 0.240 |
Why?
|
| Neurofilament Proteins | 1 | 2024 | 34 | 0.240 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2024 | 25 | 0.230 |
Why?
|
| Receptors, Odorant | 1 | 2024 | 47 | 0.230 |
Why?
|
| Mental Disorders | 1 | 2012 | 887 | 0.230 |
Why?
|
| Hippocampus | 5 | 2020 | 976 | 0.230 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2023 | 6 | 0.230 |
Why?
|
| Oleic Acids | 1 | 2023 | 15 | 0.230 |
Why?
|
| Chlorambucil | 1 | 2023 | 26 | 0.220 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 342 | 0.220 |
Why?
|
| Neurons | 8 | 2018 | 2462 | 0.220 |
Why?
|
| Hemostasis | 1 | 2003 | 99 | 0.220 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2022 | 224 | 0.220 |
Why?
|
| Cerebral Infarction | 1 | 2003 | 72 | 0.210 |
Why?
|
| Muscle Contraction | 1 | 2003 | 230 | 0.210 |
Why?
|
| Free Radical Scavengers | 1 | 2003 | 84 | 0.210 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2003 | 198 | 0.210 |
Why?
|
| Family | 1 | 2007 | 762 | 0.210 |
Why?
|
| Reference Values | 4 | 2015 | 1156 | 0.210 |
Why?
|
| Telencephalon | 1 | 2002 | 9 | 0.210 |
Why?
|
| Xenon | 2 | 2017 | 22 | 0.210 |
Why?
|
| Carbon | 2 | 2023 | 163 | 0.200 |
Why?
|
| Calpain | 4 | 2022 | 72 | 0.200 |
Why?
|
| Spinal Cord Injuries | 2 | 2022 | 349 | 0.200 |
Why?
|
| Epilepsy, Post-Traumatic | 1 | 2021 | 12 | 0.200 |
Why?
|
| Radiography | 5 | 2015 | 1988 | 0.200 |
Why?
|
| Neurologic Examination | 2 | 2014 | 268 | 0.200 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 134 | 0.200 |
Why?
|
| Consciousness Disorders | 1 | 2021 | 27 | 0.200 |
Why?
|
| Patient Acuity | 1 | 2021 | 76 | 0.200 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2281 | 0.190 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 5182 | 0.190 |
Why?
|
| Neuropsychological Tests | 3 | 2021 | 1167 | 0.190 |
Why?
|
| Hyperthermia, Induced | 1 | 2005 | 510 | 0.190 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 562 | 0.180 |
Why?
|
| Treatment Outcome | 13 | 2021 | 33797 | 0.180 |
Why?
|
| Information Dissemination | 1 | 2023 | 265 | 0.180 |
Why?
|
| Withholding Treatment | 2 | 2021 | 155 | 0.180 |
Why?
|
| Cysteine Proteases | 1 | 2020 | 7 | 0.180 |
Why?
|
| Computer Simulation | 3 | 2017 | 1523 | 0.180 |
Why?
|
| Anesthesia | 1 | 2024 | 302 | 0.180 |
Why?
|
| Cathepsin B | 1 | 2020 | 35 | 0.180 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 30875 | 0.180 |
Why?
|
| Single-Blind Method | 1 | 2021 | 405 | 0.170 |
Why?
|
| Astrocytes | 4 | 2022 | 405 | 0.170 |
Why?
|
| Cholesterol | 1 | 2023 | 679 | 0.170 |
Why?
|
| Hydrocephalus | 2 | 2017 | 260 | 0.170 |
Why?
|
| Persistent Vegetative State | 2 | 2021 | 11 | 0.170 |
Why?
|
| Tissue and Organ Procurement | 1 | 2002 | 235 | 0.170 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 5082 | 0.170 |
Why?
|
| Body Fluids | 1 | 2020 | 124 | 0.160 |
Why?
|
| Mice | 17 | 2023 | 35983 | 0.160 |
Why?
|
| Cognition | 2 | 2023 | 983 | 0.160 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 15218 | 0.160 |
Why?
|
| ROC Curve | 4 | 2016 | 1220 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2004 | 1157 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2016 | 1075 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 5436 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 1539 | 0.150 |
Why?
|
| Spatial Memory | 1 | 2017 | 41 | 0.150 |
Why?
|
| Patient Admission | 1 | 2019 | 236 | 0.150 |
Why?
|
| Life Support Care | 1 | 2017 | 51 | 0.140 |
Why?
|
| Hypernatremia | 1 | 2017 | 29 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 351 | 0.140 |
Why?
|
| Proteolysis | 2 | 2021 | 380 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2018 | 255 | 0.140 |
Why?
|
| Spectrin | 2 | 2009 | 83 | 0.140 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2017 | 86 | 0.140 |
Why?
|
| Calcium | 1 | 2003 | 1645 | 0.140 |
Why?
|
| Caspase 3 | 3 | 2014 | 483 | 0.140 |
Why?
|
| Microglia | 2 | 2017 | 176 | 0.140 |
Why?
|
| rho-Associated Kinases | 1 | 2017 | 82 | 0.140 |
Why?
|
| Diffusion Tensor Imaging | 4 | 2022 | 280 | 0.140 |
Why?
|
| Probability | 1 | 2019 | 875 | 0.140 |
Why?
|
| Retrospective Studies | 10 | 2024 | 39627 | 0.140 |
Why?
|
| DNA Damage | 2 | 2004 | 1976 | 0.140 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2017 | 89 | 0.140 |
Why?
|
| Likelihood Functions | 1 | 2017 | 221 | 0.140 |
Why?
|
| Hypoxia, Brain | 1 | 2016 | 36 | 0.140 |
Why?
|
| Maze Learning | 2 | 2017 | 140 | 0.140 |
Why?
|
| Predictive Value of Tests | 6 | 2016 | 4980 | 0.140 |
Why?
|
| Aftercare | 1 | 2018 | 255 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 7929 | 0.140 |
Why?
|
| Unconsciousness | 1 | 2016 | 21 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 328 | 0.140 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2012 | 224 | 0.140 |
Why?
|
| Morbidity | 1 | 2017 | 403 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 675 | 0.130 |
Why?
|
| Encephalitis | 1 | 2017 | 155 | 0.130 |
Why?
|
| Blood Gas Analysis | 2 | 2008 | 106 | 0.130 |
Why?
|
| Motor Activity | 3 | 2017 | 718 | 0.130 |
Why?
|
| Laser-Doppler Flowmetry | 3 | 2010 | 66 | 0.130 |
Why?
|
| Algorithms | 4 | 2020 | 3908 | 0.130 |
Why?
|
| Lateral Ventricles | 1 | 2015 | 26 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 641 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 297 | 0.120 |
Why?
|
| Inflammation | 2 | 2023 | 2526 | 0.120 |
Why?
|
| Consensus | 4 | 2023 | 1099 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2020 | 784 | 0.120 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2014 | 15 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 531 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2019 | 581 | 0.120 |
Why?
|
| Immunoassay | 1 | 2014 | 214 | 0.110 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2014 | 103 | 0.110 |
Why?
|
| Cultural Diversity | 1 | 2014 | 80 | 0.110 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 121 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2014 | 151 | 0.110 |
Why?
|
| Quality of Life | 3 | 2023 | 4719 | 0.110 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2014 | 146 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2020 | 2255 | 0.110 |
Why?
|
| Wounds, Gunshot | 1 | 2014 | 147 | 0.110 |
Why?
|
| Membrane Potentials | 2 | 2005 | 464 | 0.110 |
Why?
|
| tau Proteins | 1 | 2014 | 216 | 0.110 |
Why?
|
| Intracranial Hypotension | 1 | 2012 | 12 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2014 | 725 | 0.110 |
Why?
|
| Partial Pressure | 1 | 2012 | 37 | 0.100 |
Why?
|
| Nanotubes, Carbon | 1 | 2012 | 30 | 0.100 |
Why?
|
| Vascular Resistance | 2 | 2003 | 216 | 0.100 |
Why?
|
| Research Design | 2 | 2022 | 1566 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 4506 | 0.100 |
Why?
|
| I-kappa B Proteins | 1 | 2012 | 178 | 0.100 |
Why?
|
| Superoxide Dismutase | 2 | 2023 | 270 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2422 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2017 | 771 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4332 | 0.100 |
Why?
|
| Hospital Mortality | 2 | 2015 | 1313 | 0.100 |
Why?
|
| Sagittal Sinus Thrombosis | 1 | 2011 | 4 | 0.100 |
Why?
|
| Superior Sagittal Sinus | 1 | 2011 | 4 | 0.100 |
Why?
|
| Minority Groups | 1 | 2014 | 319 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2014 | 312 | 0.100 |
Why?
|
| Acute Disease | 3 | 2020 | 2518 | 0.100 |
Why?
|
| Axons | 1 | 2015 | 443 | 0.100 |
Why?
|
| Affect | 1 | 2013 | 303 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 3865 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2020 | 6022 | 0.090 |
Why?
|
| Skull Fractures | 1 | 2011 | 48 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2011 | 133 | 0.090 |
Why?
|
| Neurophysins | 1 | 2010 | 5 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2014 | 417 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 1439 | 0.090 |
Why?
|
| Informed Consent | 1 | 2014 | 412 | 0.090 |
Why?
|
| Vasopressins | 1 | 2010 | 75 | 0.090 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2010 | 34 | 0.090 |
Why?
|
| Ethanol | 1 | 2012 | 270 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 593 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2014 | 599 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 1234 | 0.090 |
Why?
|
| Random Allocation | 2 | 2019 | 747 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 519 | 0.090 |
Why?
|
| Incidence | 2 | 2021 | 5839 | 0.090 |
Why?
|
| Brain Edema | 1 | 2010 | 95 | 0.090 |
Why?
|
| Mice, Knockout | 4 | 2017 | 5837 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 1152 | 0.090 |
Why?
|
| Models, Biological | 3 | 2017 | 3226 | 0.090 |
Why?
|
| Hypotension | 2 | 2019 | 236 | 0.080 |
Why?
|
| Extracellular Fluid | 1 | 2008 | 19 | 0.080 |
Why?
|
| Protein Precursors | 1 | 2010 | 250 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 592 | 0.080 |
Why?
|
| United States | 6 | 2023 | 15964 | 0.080 |
Why?
|
| Risk Factors | 4 | 2021 | 17819 | 0.080 |
Why?
|
| Nerve Degeneration | 1 | 2009 | 163 | 0.080 |
Why?
|
| Genotype | 2 | 2017 | 4108 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 333 | 0.070 |
Why?
|
| Intracranial Hemorrhages | 2 | 2021 | 116 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 6164 | 0.070 |
Why?
|
| Hematoma, Subdural | 1 | 2007 | 30 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 1575 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2010 | 293 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 296 | 0.070 |
Why?
|
| Models, Animal | 2 | 2017 | 675 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2012 | 645 | 0.070 |
Why?
|
| Observation | 1 | 2007 | 52 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 4180 | 0.070 |
Why?
|
| Cause of Death | 1 | 2010 | 784 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2020 | 2905 | 0.070 |
Why?
|
| Patient Selection | 1 | 2014 | 2042 | 0.070 |
Why?
|
| Stroke | 1 | 2014 | 1091 | 0.070 |
Why?
|
| Peptides | 2 | 2022 | 1528 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2010 | 607 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 5 | 2015 | 7210 | 0.070 |
Why?
|
| Cerebral Ventricles | 1 | 2006 | 106 | 0.060 |
Why?
|
| Muscle Relaxation | 1 | 2005 | 22 | 0.060 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 1239 | 0.060 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2005 | 17 | 0.060 |
Why?
|
| Peptide Hydrolases | 2 | 2022 | 264 | 0.060 |
Why?
|
| Electric Conductivity | 1 | 2005 | 99 | 0.060 |
Why?
|
| Cerebral Hemorrhage, Traumatic | 1 | 2004 | 4 | 0.060 |
Why?
|
| Dendrites | 2 | 2017 | 206 | 0.060 |
Why?
|
| Diffuse Axonal Injury | 1 | 2024 | 10 | 0.060 |
Why?
|
| Feedback, Physiological | 1 | 2005 | 194 | 0.060 |
Why?
|
| Texas | 1 | 2015 | 6416 | 0.060 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 208 | 0.060 |
Why?
|
| Sodium Chloride | 1 | 2004 | 172 | 0.060 |
Why?
|
| Potassium Channels | 1 | 2005 | 197 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2007 | 496 | 0.060 |
Why?
|
| Viscosity | 1 | 2003 | 43 | 0.060 |
Why?
|
| Dalteparin | 1 | 2003 | 11 | 0.060 |
Why?
|
| Charcoal | 1 | 2023 | 9 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2021 | 6832 | 0.060 |
Why?
|
| Elasticity | 1 | 2003 | 135 | 0.060 |
Why?
|
| Age Factors | 4 | 2017 | 5495 | 0.060 |
Why?
|
| Nitrates | 1 | 2003 | 45 | 0.060 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2003 | 11 | 0.050 |
Why?
|
| Nitrites | 1 | 2003 | 68 | 0.050 |
Why?
|
| Enoxaparin | 1 | 2003 | 57 | 0.050 |
Why?
|
| Dominance, Cerebral | 1 | 2003 | 79 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2011 | 2085 | 0.050 |
Why?
|
| Consent Forms | 1 | 2002 | 27 | 0.050 |
Why?
|
| Catalase | 1 | 2003 | 75 | 0.050 |
Why?
|
| Pyruvic Acid | 1 | 2004 | 134 | 0.050 |
Why?
|
| Caspase 6 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 275 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2002 | 38 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2022 | 28 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 504 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2004 | 312 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2018 | 56 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2004 | 336 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 365 | 0.050 |
Why?
|
| Neurogranin | 1 | 2021 | 2 | 0.050 |
Why?
|
| Brain Death | 1 | 2002 | 59 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2021 | 97 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2017 | 5687 | 0.050 |
Why?
|
| Cell Survival | 2 | 2010 | 3080 | 0.050 |
Why?
|
| Decision Making | 1 | 2009 | 1245 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 5160 | 0.050 |
Why?
|
| Neurosurgery | 1 | 2002 | 118 | 0.050 |
Why?
|
| Hypoxia | 1 | 2004 | 467 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2024 | 4988 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2014 | 5785 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2023 | 307 | 0.050 |
Why?
|
| Survival Rate | 4 | 2017 | 12488 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 301 | 0.050 |
Why?
|
| Child | 4 | 2014 | 30422 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 5040 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1757 | 0.050 |
Why?
|
| Vimentin | 1 | 2021 | 265 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 2316 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2022 | 342 | 0.040 |
Why?
|
| Amygdala | 1 | 2020 | 120 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 503 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 379 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 78 | 0.040 |
Why?
|
| Sepsis | 1 | 2005 | 689 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 218 | 0.040 |
Why?
|
| Public Health | 1 | 2022 | 298 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 390 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 1067 | 0.040 |
Why?
|
| Thy-1 Antigens | 1 | 2018 | 52 | 0.040 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2002 | 330 | 0.040 |
Why?
|
| Inpatients | 1 | 2023 | 692 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2007 | 2126 | 0.040 |
Why?
|
| Pamphlets | 1 | 2018 | 33 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 555 | 0.040 |
Why?
|
| Glucose | 1 | 2004 | 1255 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 986 | 0.040 |
Why?
|
| Craniotomy | 1 | 2020 | 306 | 0.040 |
Why?
|
| Gliosis | 1 | 2017 | 44 | 0.040 |
Why?
|
| Prosencephalon | 1 | 2017 | 50 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 791 | 0.040 |
Why?
|
| Military Medicine | 1 | 2017 | 54 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2017 | 116 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 771 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2024 | 6493 | 0.030 |
Why?
|
| Disease Progression | 2 | 2020 | 6887 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2002 | 936 | 0.030 |
Why?
|
| Resuscitation | 1 | 2019 | 265 | 0.030 |
Why?
|
| Patient Care | 1 | 2017 | 151 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2020 | 1837 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 4511 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 2015 | 30 | 0.030 |
Why?
|
| South America | 1 | 2015 | 54 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 1372 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 704 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2002 | 1931 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2017 | 410 | 0.030 |
Why?
|
| Adie Syndrome | 1 | 2014 | 4 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2015 | 113 | 0.030 |
Why?
|
| Infant | 1 | 2010 | 13924 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2020 | 12205 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 5113 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1858 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2015 | 359 | 0.030 |
Why?
|
| Ankyrins | 1 | 2015 | 110 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2010 | 16980 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 565 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 729 | 0.030 |
Why?
|
| Oximetry | 1 | 2014 | 185 | 0.030 |
Why?
|
| Benchmarking | 1 | 2015 | 284 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 801 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2014 | 161 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 480 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 917 | 0.030 |
Why?
|
| Hematinics | 1 | 2014 | 110 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5876 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 9310 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 729 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 3173 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2017 | 1482 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 689 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2430 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 534 | 0.030 |
Why?
|
| Motorcycles | 1 | 2011 | 8 | 0.020 |
Why?
|
| Action Potentials | 1 | 2015 | 597 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 2228 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2002 | 4191 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2011 | 217 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2012 | 245 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 3418 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 117 | 0.020 |
Why?
|
| Protein Stability | 1 | 2011 | 374 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 5436 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2014 | 635 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1062 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 750 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 1110 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2014 | 374 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 524 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 196 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2014 | 993 | 0.020 |
Why?
|
| Neurochemistry | 1 | 2008 | 5 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 4876 | 0.020 |
Why?
|
| Pupil | 1 | 2009 | 63 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 459 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 2288 | 0.020 |
Why?
|
| Health Personnel | 1 | 2014 | 644 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2014 | 1189 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 1345 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 991 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1617 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 1706 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 7817 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 1582 | 0.020 |
Why?
|
| Silicones | 1 | 2005 | 60 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2191 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 829 | 0.010 |
Why?
|
| Rifampin | 1 | 2005 | 220 | 0.010 |
Why?
|
| Minocycline | 1 | 2005 | 189 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2009 | 1330 | 0.010 |
Why?
|
| Pia Mater | 1 | 2003 | 17 | 0.010 |
Why?
|
| Arterioles | 1 | 2003 | 35 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 108 | 0.010 |
Why?
|
| Prealbumin | 1 | 2003 | 38 | 0.010 |
Why?
|
| Cobra Cardiotoxin Proteins | 1 | 2002 | 7 | 0.010 |
Why?
|
| Capillaries | 1 | 2003 | 105 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2003 | 235 | 0.010 |
Why?
|
| Nerve Growth Factor | 1 | 2002 | 43 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2002 | 134 | 0.010 |
Why?
|
| Hormones | 1 | 2003 | 293 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2003 | 284 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 536 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 409 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2003 | 797 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2003 | 686 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2003 | 742 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2002 | 726 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 915 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 2108 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 2490 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 2465 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 3655 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 1773 | 0.010 |
Why?
|
| Mitochondria | 1 | 2003 | 1319 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2002 | 1312 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 6970 | 0.000 |
Why?
|